Chronic Lymphocytic Leukemia | Specialty

Frontline Ibrutinib Highly Effective Across Subgroups for Elderly Patients With CLL/SLL

March 18th 2016

Frontline treatment with ibrutinib reduced the risk of progression or death by 84% compared with single-agent chlorambucil for elderly patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

New Agents Transform Treatment of Non-Hodgkin Lymphoma

March 16th 2016

Mitchell Smith, MD, discusses advancements in the field of non-Hodgkin lymphoma.

Expanded Indication Sought for Ofatumumab in CLL

March 15th 2016

A supplemental new drug application has been submitted to the FDA for ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia.

FDA Approves Ibrutinib for Frontline CLL

March 4th 2016

The FDA has approved ibrutinib (Imbruvica) for the frontline treatment of chronic lymphocytic leukemia based on data from the RESONATE-2 trial.

Kipps on Impact of Potential Venetoclax Approval and Other Novel CLL Agents

February 25th 2016

Thomas Kipps, MD, PhD, provides insight on the potential impact of an FDA approval for venetoclax, the management of tumor lysis syndrome associated with venetoclax, and combination possibilities for the agent.

Upcoming Approvals, Combinations Will Transform CLL Treatment

February 25th 2016

Victor Y. Yazbeck, MD, discusses the potential for venetoclax and idelalisib, both as single agents and in combination with other agents, and what questions remain regarding both therapies in CLL.

Expert Discusses Role of Venetoclax and Future of CLL Care

February 25th 2016

Jeffrey Jones, MD, discusses exciting data with venetoclax, the role it is likely to have in the treatment paradigm of CLL, and what role it may have alongside ibrutinib and idelalisib.

Dr. Farrukh Awan Explains Syk Inhibitor in CLL

February 24th 2016

Farrukh Awan, MBBS, assistant professor of internal medicine, Ohio State University, discusses the role for spleen tyrosine kinase (Syk) inhibitor for the treatment of chronic lymphocytic leukemia (CLL).

Blinatumomab Nears 70% Response Rate in Non-Hodgkin Lymphoma

February 18th 2016

The anti-CD19 agent blinatumomab (Blincyto) induced a response rate of 69% in patients with non-Hodgkin Lymphoma.

SYK Inhibitor Shows Promise in CLL

February 18th 2016

Entospletinib (GS-9973) has shown early promise as a treatment for pretreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Allogeneic CAR T-Cell Therapy Shows Promising Efficacy Without GVHD

January 29th 2016

Treatment with allogeneic anti–CD19 chimeric antigen receptor–modified T cell therapy induced complete remissions in 30% of patients with advanced progressive B-cell malignancies without causing graft-versus-host disease.

FDA Approval in Myeloma, Expanded Approval in Melanoma, GI Cancer Symposium Highlights, and More

January 28th 2016

Dr. Yazbeck on Idelalisib Plus BR in Relapsed/Refractory CLL

January 25th 2016

Victor Y. Yazbeck, MD, assistant professor, Hematology-Oncology, Internal Medicine, Virginia Commonwealth University (VCU) School of Medicine, VCU Massey Cancer Center, discusses a phase III study examining idelalisib plus bendamustine rituximab in patients with relapsed/refractory chronic lymphocytic leukemia.

FDA Grants Venetoclax Combination Breakthrough Designation in CLL

January 21st 2016

Venetoclax has received an FDA breakthrough therapy designation for use in combination with rituximab to treat patients with relapsed/refractory chronic lymphocytic leukemia.

Maintenance Ofatumumab Approved in CLL

January 19th 2016

FDA Approves Maintenance Ofatumumab in CLL

January 19th 2016

The FDA has approved ofatumumab (Arzerra) for the extended treatment of patients with recurrent or progressive chronic lymphocytic leukemia who are in complete or partial response following at least two lines of therapy.

Emerging Chronic Lymphocytic Leukemia Therapies

January 19th 2016

Venetoclax in Chronic Lymphocytic Leukemia

January 19th 2016

Evaluating the Role of Idelalisib in CLL

January 19th 2016

Mechanisms of Ibrutinib Resistance in CLL

January 19th 2016